Health Care & Life Sciences » Biotechnology | Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC ADR
Stock Exchange Frankfurt Stock Exchange
EPS
EUR0.89
Market Cap
EUR345.6 M
Shares Outstanding
104.45 M
Public Float
-
Adaptimmune Therapeutics PLC ADR
Stock Exchange NASDAQ Stock Market
EPS
$1.03
Market Cap
$387.49 M
Shares Outstanding
104.71 M
Public Float
86.21 M

Profile

Address
60 Jubilee Avenue
Abingdon Oxfordshire OX14 4RX
United Kingdom
Employees -
Website http://adaptimmune.com
Updated 07/08/2019
Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K.

Financials

View All

James Julian Noble
Chief Executive Officer & Executive Director
David M. Mott
Chairman